News

Increased levels of certain lipids in the brain may be an early sign of Parkinson’s disease (PD), and could help identify patients at risk, as well as provide opportunities for early treatment, a study has found. The study, “Glycosphingolipid levels and glucocerebrosidase activity are altered in…

Researchers have generated a new mouse model that can be used for in-depth studies of disease mechanisms and new therapeutic possibilities for Parkinson’s disease. Although the function of the protein α-synuclein is unknown, its accumulation in clumps known as Lewy bodies, hallmarks of Parkinson’s disease, suggests this protein plays a…

A mild traumatic brain injury (TBI), including a concussion, can increase a person’s risk of developing Parkinson’s disease by more than 50 percent, a study conducted in U.S. military veterans reports. The study, “Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study,”…

The first patient with advanced Parkinson’s has been treated in a pivotal Phase 3 trial using MRI-guided focused ultrasound to address major motor symptoms of the disease. The multisite, randomized, and double-blinded clinical trial (NCT03319485) is evaluating the safety and effectiveness of MRI-guided focused ultrasound delivered to affected brain areas…

Deficits in short-term memory, known as working memory, may underlie the compulsive “binge eating” observed in some Parkinson’s patients undergoing dopamine replacement therapy, a new study suggests. The research “Reward sensitivity in Parkinson’s patients with binge eating” was published in the journal Parkinsonism and Related Disorders. Parkinson’s patients…

A protein abundant in fish, called β-parvalbumin, can prevent alpha-synuclein aggregation, which is a hallmark of Parkinson’s disease and other neurological disorders, according to a recent study. This suggests that eating more fish may help prevent toxic events associated with alpha-synuclein aggregation and progression of several neurological diseases. This finding…

Peptron recently obtained an exclusive worldwide license of intellectual property from the National Institute on Aging (NIA), a National Institutes of Health (NIH) center, covering the delivery and use of sustained-release (SR) exenatide in the treatment of Parkinson’s disease and other neurodegenerative disorders. The intellectual property…

High-intensity exercise is not only safe and feasible, but it can also delay disease progression in early stage Parkinson’s patients, results of a Phase 2 trial report. The study, “Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease,…

Nearly all Parkinson’s disease patients experience non-movement symptoms, such as sleep disturbances or depression, which affect their quality of life as much as movement-related symptoms, according to an online survey of 700 participants, nearly 600 of whom completed it in full. Patients’ caregivers are those most likely to detect non-movement…

A molecule created by the brain burning fat for fuel can accumulate in some people and turn toxic, playing a key role in their possibly developing Parkinson’s disease,  researchers at Purdue University report. These findings, in the study “Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: implications for Parkinson’s…